ClinConnect ClinConnect Logo
Search / Trial NCT00647517

Tramadol/Acetaminophen(Ultracet) AS add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis

Launched by CHUNG SHAN MEDICAL UNIVERSITY · Mar 28, 2008

Trial Information

Current as of April 28, 2025

Completed

Keywords

ClinConnect Summary

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis causing back pain, peripheral arthritis and enthesitis due to genetic background and autoimmunity. Patients with ankylosing spondylitis usually suffered from chronic pain over spine and peripheral joints since their second or third decades. It may also cause severe social and psychological burden to patients and their family.

Exercise and non-steroid anti-inflammatory drugs (NSAID) are the standard first-line treatments for AS(1). Only 50% of patients with AS reach the ASAS response criteria(2) in clinical trials. Patients wit...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Diagnosis of AS, as defined by Modified New York Criteria for Ankylosing Spondylitis
  • 2. Active AS, defined by Bath ankylosing spondylitis disease activity index (BASDAI) \>3 cm at screening visit.
  • 3. Between 18 and 70 years of age.
  • Exclusion Criteria:
  • 1. Change of dosage of disease modifying antirheumatic drugs (DMARDs) including glucocorticoid, hydroxychloroquine, sulphasalazine, and methotrexate within 4 weeks of baseline.
  • 2. Change of dosage of biological agents within 4 weeks of baseline.
  • 3. Abnormality in chemistry profiles: serum creatinine 3.0 mg/dl; alanine aminotransferase (ALT\[SGPT\]) 5 times the laboratory's upper limit of normal.
  • 4. Pregnant or breast-feeding women.

About Chung Shan Medical University

Chung Shan Medical University is a distinguished academic institution dedicated to advancing medical education, research, and healthcare services. As a clinical trial sponsor, the university leverages its expertise in medical sciences and innovative research methodologies to conduct rigorous and ethically sound clinical studies. With a commitment to enhancing patient care and contributing to the global body of medical knowledge, Chung Shan Medical University collaborates with healthcare professionals and research institutions to explore new therapeutic interventions and improve clinical outcomes. Through its comprehensive approach to research, the university plays a pivotal role in fostering advancements in medical science and public health.

Locations

Taichung, , Taiwan

Patients applied

0 patients applied

Trial Officials

James WEI, MD, PhD.

Principal Investigator

Department of rheumatology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials